Prodrug (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Prodrug" in English language version.

Last modified: 20:17:58, 23 September 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

1713nih.gov

5^th place

1310doi.org

2^nd place

43semanticscholar.org

15^th place

8^th place

42books.google.com

3^rd place

22web.archive.org

1^st place

21zenodo.org

737^th place

426^th place

21adsabs.harvard.edu

14^th place

9^th place

11worldcat.org

4^th place

11iupac.org

1,291^st place

1,832^nd place

11ukmi.nhs.uk

low place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Wu KM, Farrelly JG (July 2007). "Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology". Toxicology. 236 (1–2): 1–6. Bibcode:2007Toxgy.236....1W. doi:10.1016/j.tox.2007.04.005. PMID 17507137.; Table 1

books.google.com (Global: 3^rd place; English: 3^rd place)

Hacker M, Messer WS, Bachmann KA (2009). "Chapter 10.5: Elimination (Metabolism and Excretion)". Pharmacology: Principles and Practice. Academic Press. pp. 216–217. ISBN 978-0080919225.
Schrör K (2009). Acetylsalicylic acid. Wiley. ISBN 978-3527321094.

doi.org (Global: 2^nd place; English: 2^nd place)

Rautio J, Meanwell NA, Di L, Hageman MJ (August 2018). "The expanding role of prodrugs in contemporary drug design and development". Nature Reviews. Drug Discovery. 17 (8): 559–587. doi:10.1038/nrd.2018.46. PMID 29700501. S2CID 19489166.
Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC (2009). "The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine". Current Medicinal Chemistry. 16 (33): 4481–4489. doi:10.2174/092986709789712835. PMID 19835561.
Stella VJ, Charman WN, Naringrekar VH (May 1985). "Prodrugs. Do they have advantages in clinical practice?". Drugs. 29 (5): 455–473. doi:10.2165/00003495-198529050-00002. PMID 3891303. S2CID 195692168.
Lillethorup, Ida Aaberg; Hemmingsen, Andreas Victor; Qvortrup, Katrine (2025-03-19). "Prodrugs and their activation mechanisms for brain drug delivery". RSC medicinal chemistry. 16 (3): 1037–1048. doi:10.1039/d4md00788c. ISSN 2632-8682. PMC 11740913. PMID 39829971.
Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA (1998). "Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)". Pure and Applied Chemistry. 70 (5): 1129–1143. doi:10.1351/pac199870051129.
Vert M, Doi Y, Hellwich KH, Hess M, Hodge P, Kubisa P, Rinaudo M, Schué F (2012). "Terminology for biorelated polymers and applications (IUPAC Recommendations 2012)" (PDF). Pure and Applied Chemistry. 84 (2): 377–410. doi:10.1351/PAC-REC-10-12-04. S2CID 98107080. Archived from the original (PDF) on 2015-03-19. Retrieved 2013-07-29.
Sneader W (2000). "The discovery of aspirin: a reappraisal". BMJ. 321 (7276): 1591–1594. doi:10.1136/bmj.321.7276.1591. PMC 1119266. PMID 11124191.
Wu KM (October 2009). "A New Classification of Prodrugs: Regulatory Perspectives". Pharmaceuticals. 2 (3): 77–81. doi:10.3390/ph2030077. PMC 3978533. PMID 27713225.
Wu KM, Farrelly JG (July 2007). "Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology". Toxicology. 236 (1–2): 1–6. Bibcode:2007Toxgy.236....1W. doi:10.1016/j.tox.2007.04.005. PMID 17507137.; Table 1
Wu KM (October 2009). "A New Classification of Prodrugs: Regulatory Perspectives". Pharmaceuticals. 2 (3): 77–81. doi:10.3390/ph2030077. PMC 3978533. PMID 27713225.; Table 1

iupac.org (Global: 1,291^st place; English: 1,832^nd place)

pac.iupac.org

Vert M, Doi Y, Hellwich KH, Hess M, Hodge P, Kubisa P, Rinaudo M, Schué F (2012). "Terminology for biorelated polymers and applications (IUPAC Recommendations 2012)" (PDF). Pure and Applied Chemistry. 84 (2): 377–410. doi:10.1351/PAC-REC-10-12-04. S2CID 98107080. Archived from the original (PDF) on 2015-03-19. Retrieved 2013-07-29.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Rautio J, Meanwell NA, Di L, Hageman MJ (August 2018). "The expanding role of prodrugs in contemporary drug design and development". Nature Reviews. Drug Discovery. 17 (8): 559–587. doi:10.1038/nrd.2018.46. PMID 29700501. S2CID 19489166.
Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC (2009). "The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine". Current Medicinal Chemistry. 16 (33): 4481–4489. doi:10.2174/092986709789712835. PMID 19835561.
Stella VJ, Charman WN, Naringrekar VH (May 1985). "Prodrugs. Do they have advantages in clinical practice?". Drugs. 29 (5): 455–473. doi:10.2165/00003495-198529050-00002. PMID 3891303. S2CID 195692168.
Lillethorup, Ida Aaberg; Hemmingsen, Andreas Victor; Qvortrup, Katrine (2025-03-19). "Prodrugs and their activation mechanisms for brain drug delivery". RSC medicinal chemistry. 16 (3): 1037–1048. doi:10.1039/d4md00788c. ISSN 2632-8682. PMC 11740913. PMID 39829971.
Sneader W (2000). "The discovery of aspirin: a reappraisal". BMJ. 321 (7276): 1591–1594. doi:10.1136/bmj.321.7276.1591. PMC 1119266. PMID 11124191.
Wu KM (October 2009). "A New Classification of Prodrugs: Regulatory Perspectives". Pharmaceuticals. 2 (3): 77–81. doi:10.3390/ph2030077. PMC 3978533. PMID 27713225.
Wu KM, Farrelly JG (July 2007). "Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology". Toxicology. 236 (1–2): 1–6. Bibcode:2007Toxgy.236....1W. doi:10.1016/j.tox.2007.04.005. PMID 17507137.; Table 1
Wu KM (October 2009). "A New Classification of Prodrugs: Regulatory Perspectives". Pharmaceuticals. 2 (3): 77–81. doi:10.3390/ph2030077. PMC 3978533. PMID 27713225.; Table 1

ncbi.nlm.nih.gov

Lillethorup, Ida Aaberg; Hemmingsen, Andreas Victor; Qvortrup, Katrine (2025-03-19). "Prodrugs and their activation mechanisms for brain drug delivery". RSC medicinal chemistry. 16 (3): 1037–1048. doi:10.1039/d4md00788c. ISSN 2632-8682. PMC 11740913. PMID 39829971.
Sneader W (2000). "The discovery of aspirin: a reappraisal". BMJ. 321 (7276): 1591–1594. doi:10.1136/bmj.321.7276.1591. PMC 1119266. PMID 11124191.
Wu KM (October 2009). "A New Classification of Prodrugs: Regulatory Perspectives". Pharmaceuticals. 2 (3): 77–81. doi:10.3390/ph2030077. PMC 3978533. PMID 27713225.
Wu KM (October 2009). "A New Classification of Prodrugs: Regulatory Perspectives". Pharmaceuticals. 2 (3): 77–81. doi:10.3390/ph2030077. PMC 3978533. PMID 27713225.; Table 1

pmc.ncbi.nlm.nih.gov

Lillethorup, Ida Aaberg; Hemmingsen, Andreas Victor; Qvortrup, Katrine (2025-03-19). "Prodrugs and their activation mechanisms for brain drug delivery". RSC medicinal chemistry. 16 (3): 1037–1048. doi:10.1039/d4md00788c. ISSN 2632-8682. PMC 11740913. PMID 39829971.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Rautio J, Meanwell NA, Di L, Hageman MJ (August 2018). "The expanding role of prodrugs in contemporary drug design and development". Nature Reviews. Drug Discovery. 17 (8): 559–587. doi:10.1038/nrd.2018.46. PMID 29700501. S2CID 19489166.
Stella VJ, Charman WN, Naringrekar VH (May 1985). "Prodrugs. Do they have advantages in clinical practice?". Drugs. 29 (5): 455–473. doi:10.2165/00003495-198529050-00002. PMID 3891303. S2CID 195692168.
Vert M, Doi Y, Hellwich KH, Hess M, Hodge P, Kubisa P, Rinaudo M, Schué F (2012). "Terminology for biorelated polymers and applications (IUPAC Recommendations 2012)" (PDF). Pure and Applied Chemistry. 84 (2): 377–410. doi:10.1351/PAC-REC-10-12-04. S2CID 98107080. Archived from the original (PDF) on 2015-03-19. Retrieved 2013-07-29.

ukmi.nhs.uk (Global: low place; English: low place)

UK Medicines Information Pharmacists Group. New Medicines on the Market: Desloratadine. Archived 2007-10-11 at the Wayback Machine June 2001.

web.archive.org (Global: 1^st place; English: 1^st place)

Vert M, Doi Y, Hellwich KH, Hess M, Hodge P, Kubisa P, Rinaudo M, Schué F (2012). "Terminology for biorelated polymers and applications (IUPAC Recommendations 2012)" (PDF). Pure and Applied Chemistry. 84 (2): 377–410. doi:10.1351/PAC-REC-10-12-04. S2CID 98107080. Archived from the original (PDF) on 2015-03-19. Retrieved 2013-07-29.
UK Medicines Information Pharmacists Group. New Medicines on the Market: Desloratadine. Archived 2007-10-11 at the Wayback Machine June 2001.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Lillethorup, Ida Aaberg; Hemmingsen, Andreas Victor; Qvortrup, Katrine (2025-03-19). "Prodrugs and their activation mechanisms for brain drug delivery". RSC medicinal chemistry. 16 (3): 1037–1048. doi:10.1039/d4md00788c. ISSN 2632-8682. PMC 11740913. PMID 39829971.

zenodo.org (Global: 737^th place; English: 426^th place)

Wu KM, Farrelly JG (July 2007). "Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology". Toxicology. 236 (1–2): 1–6. Bibcode:2007Toxgy.236....1W. doi:10.1016/j.tox.2007.04.005. PMID 17507137.; Table 1

Prodrug (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

iupac.org (Global: 1,291st place; English: 1,832nd place)